Conversion Chemotherapy for Locally Advanced Pancreatic Carcinoma: FOLFIRINOX or Gemcitabine?

Kaibo Guo

Kaibo Guo, MD, Department of Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China; Jiamin Lu, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China; Xinlei Zhou, MD, The Third Clinical Medical School, the Rehabilitation Medical School, Zhejiang Chinese Medical University, Hangzhou, China; and Song Zheng, PhD, Department of Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China

Jiamin Lu

Xinlei Zhou

Kaibo Guo, MD, Department of Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China; Jiamin Lu, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China; Xinlei Zhou, MD, The Third Clinical Medical School, the Rehabilitation Medical School, Zhejiang Chinese Medical University, Hangzhou, China; and Song Zheng, PhD, Department of Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China

Song Zheng